tetano
Editor, Senior Moderator
J Infect Dev Ctries
. 2022 Jul 28;16(7):1126-1130.
doi: 10.3855/jidc.15825.
Prevalence of SARS -CoV-2 IgG/IgM antibodies among patients in Zakho City, Kurdistan, Iraq
Ali Yahya Saeed[SUP] 1 [/SUP], Mahde Saleh Assafi[SUP] 2 [/SUP], Hemin Esmael Othman[SUP] 1 [/SUP], Hogir Mohammed Shukri[SUP] 3 [/SUP]
Affiliations
Abstract
Introduction: In 2019, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the agent of Coronavirus Disease 2019 (COVID-19), spread all over the world. This global pandemic spread rapidly to more than 195 countries and caused over 200 million infections with a mortality rate of 2%. This study aimed to detect seropositivity against the SARS-CoV-2 virus among outpatients, symptomatic and asymptomatic individuals.
Methodology: A total of 489 individuals of age 5-70 years (mean 38.0 ± 17 SD) were enrolled for a cross-sectional study. They were tested for presence of SARS-CoV-2 IgM/IgG antibodies in serum samples using Enzyme-linked Immunofluorescent Assay (ALFA).
Results: A higher seroprevalence was recorded for IgM among females (34.96%) than males (28.83%). In the case of IgG, and IgG + IgM, both males and females had similar values. A significant correlation was identified between seropositivity and age; higher seropositivity (IgG, IgM, and IgG + IgM) was recorded in age groups 51-60 and ≥ 61 years, relative to the younger age groups. No significant correlation was found between symptomatic and asymptomatic individuals. No significant correlation was detected between seropositivity and RT-PCR positive and negative cases.
Conclusions: COVID-19 is spreading rapidly and there is a high percentage of asymptomatic carriers. The sensitivity of RT-PCR tests is not uniform and may not be able to detect all cases. On the other hand, serology can be used for large scale testing to detect the real extent to which the disease has spread.
Keywords: IgG; IgM; SARS-CoV-2; asymptomatic; symptomatic.
. 2022 Jul 28;16(7):1126-1130.
doi: 10.3855/jidc.15825.
Prevalence of SARS -CoV-2 IgG/IgM antibodies among patients in Zakho City, Kurdistan, Iraq
Ali Yahya Saeed[SUP] 1 [/SUP], Mahde Saleh Assafi[SUP] 2 [/SUP], Hemin Esmael Othman[SUP] 1 [/SUP], Hogir Mohammed Shukri[SUP] 3 [/SUP]
Affiliations
- PMID: 35905016
- DOI: 10.3855/jidc.15825
Abstract
Introduction: In 2019, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the agent of Coronavirus Disease 2019 (COVID-19), spread all over the world. This global pandemic spread rapidly to more than 195 countries and caused over 200 million infections with a mortality rate of 2%. This study aimed to detect seropositivity against the SARS-CoV-2 virus among outpatients, symptomatic and asymptomatic individuals.
Methodology: A total of 489 individuals of age 5-70 years (mean 38.0 ± 17 SD) were enrolled for a cross-sectional study. They were tested for presence of SARS-CoV-2 IgM/IgG antibodies in serum samples using Enzyme-linked Immunofluorescent Assay (ALFA).
Results: A higher seroprevalence was recorded for IgM among females (34.96%) than males (28.83%). In the case of IgG, and IgG + IgM, both males and females had similar values. A significant correlation was identified between seropositivity and age; higher seropositivity (IgG, IgM, and IgG + IgM) was recorded in age groups 51-60 and ≥ 61 years, relative to the younger age groups. No significant correlation was found between symptomatic and asymptomatic individuals. No significant correlation was detected between seropositivity and RT-PCR positive and negative cases.
Conclusions: COVID-19 is spreading rapidly and there is a high percentage of asymptomatic carriers. The sensitivity of RT-PCR tests is not uniform and may not be able to detect all cases. On the other hand, serology can be used for large scale testing to detect the real extent to which the disease has spread.
Keywords: IgG; IgM; SARS-CoV-2; asymptomatic; symptomatic.